3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
16
Genitourinary
8
Gastrointestinal
8
Breast
5
Sarcoma
3
Tumor-Agnostic
2
Thoracic
2
Other hematologic neoplasm
2
NET
2
Myeloid
2
Lymphoid
2
Head & Neck
2
Endocrine
2
CNS
2
Plasma cell
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Nasopharyngeal Carcinoma
1
Head and Neck Neoplasms
1
Carcinoma, Squamous Cell
1
Interventions
Cisplatin
30
pembrolizumab
24
Magnetic Resonance Spectroscopy
24
Specimen Handling
20
Cetuximab
18
Nivolumab
15
Carboplatin
14
Platinum
12
1,2-diaminocyclohexaneplatinum II citrate
12
Radiotherapy, Intensity-Modulated
11
Radiotherapy
10
Radiation
9
Paclitaxel
9
Docetaxel
8
Biopsy
8
Immunoglobulin G
7
Disulfides
7
Surveys and Questionnaires
6
Ipilimumab
6
atezolizumab
5
Fluorouracil
5
toripalimab
4
dostarlimab
4
cemiplimab
4
cabozantinib
4
Taxes
4
Gemcitabine
4
CTLA-4 Antigen
4
Bevacizumab
4
(225)Ac-DOTA-c(RGDyK)
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
olaparib
×
Head & Neck
×
30 days
×
Clear all
NCT04825990
2026-06-01
POINT
Gruppo Oncologico del Nord-Ovest
Phase 2
Active not recruiting
30 enrolled
NCT02308072
2026-05-22
ORCA-2
University College, London
Phase 1
Completed
16 enrolled